Compare stocks

CANF vs SION

Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares and Sionna Therapeutics, Inc. Common Stock

Compare the businesses

Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.

Open CANF dashboard ↗

Sionna Therapeutics, Inc. Common Stock

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; and SION-719 and SION-451, which are nucleotide-binding domain 1 stabilizers in Phase 1 trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Open SION dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗